In cases suggestive of IRIS-mediated neoplasm in patients taking an integrase inhibitor as part of their HAART regimen, it is possible that any potential perturbations to the RAG1/2 system, coupled with dysfunctional T cells or enhanced cytokine responses, may be associated with the development of symptomatic malignancy. The gene discussed is RAG1; the disease is neoplasm.